1 hour ago
1
JHVEPhoto
Shares of Precigen (NASDAQ:PGEN) added ~34% in the premarket on Friday after the U.S. Food and Drug Administration (FDA) approved its gene therapy candidate Papzimeos (zopapogene imadenovec-drba) for a tumor condition called recurrent respiratory papillomatosis (RRP).
According to the FDA, the
© FBT Company 2025. All rights are reserved
English (US) ·